Mendizova A, Brailski Kh, Dimitrov B
Vutr Boles. 1989;28(3):28-33.
The results of the treatment with the Bulgarian drug biotidin of 30 patients with endoscopically proved duodenal peptic ulcer are presented. The drug was given in a dose of 150 mg twice daily in the course of 20 days. The pain ceased up to the third day in 93.3% of the patients treated and the dyspeptic complaints vanished up to the second day of treatment in 96.6% of the patients. Following the treatment a statistically significant lowering of the indices of gastric secretion (V abd V1) and acid production (BAO, MAO, PAO) was found compared to those before the treatment. Endoscopically full epithelialization was found in 63.3% of the patient, in 33.3% of the patients the size of the ulcer diminished and in only 3.4% of the patients there was no change of the ulcer size. The ulcer epithelialization was related to the initial ulcer size. The results achieved do not differ substantially from those achieved with the English drug Zantac. In the course of treatment with biotidin no side effects were observed and no changes of the basic biochemical indices were found.
本文呈现了用保加利亚药物比奥替丁治疗30例经内镜证实为十二指肠消化性溃疡患者的结果。该药物剂量为每日两次，每次150毫克，疗程为20天。93.3%接受治疗的患者在第三天前疼痛消失，96.6%的患者在治疗第二天前消化不良症状消失。与治疗前相比，治疗后发现胃分泌指标（V abd和V1）和胃酸分泌（基础胃酸分泌量、最大胃酸分泌量、高峰胃酸分泌量）有统计学意义的降低。内镜检查发现63.3%的患者溃疡完全上皮化，33.3%的患者溃疡面积缩小，仅3.4%的患者溃疡大小无变化。溃疡上皮化与初始溃疡大小有关。所取得的结果与用英国药物雷尼替丁取得的结果没有实质性差异。在用比奥替丁治疗过程中，未观察到副作用，也未发现基本生化指标有变化。
